Kerbside Consult

The Prescription That Changes the Instructions: Gene Therapy

Gene therapy has reached patients. But who can receive it, who sets the rules—and who pays?

Cyberdoc — writing on medicine since 1995

53/2026 · 16 October 2026 · Kuala Lumpur

Preamble

For a child with severe thalassaemia, the hospital calendar can become part of childhood.

Another blood test. Another transfusion. More treatment to remove the iron that accumulates along the way.

These treatments keep patients alive. But what if we could address the inherited problem itself—giving cells instructions to produce what the body lacks?

That is the promise of gene therapy. For selected conditions, it is already clinical reality, including in Malaysia. The questions now extend beyond the laboratory: who can benefit, how safely, and who can afford it?

Cover illustration for The Prescription That Changes the Instructions: Gene Therapy, showing a doctor with a mother and child beside a DNA double helix.
Gene therapy can change the instructions a cell follows. Who can receive it, how safely, and at what cost are separate questions.

1. Treating the instructions

DNA carries much of the information our cells use to function. A gene is a stretch of DNA containing instructions for a functional product, often a protein. A change in the sequence is called a variant, sometimes described as a mutation. Many are harmless; some disrupt an important function and cause disease.

Gene therapy introduces or modifies genetic material in cells to treat disease. It may supply a working gene, change an existing sequence or alter how genetic instructions operate. [1] Think of an instruction manual: we can add an instruction, edit the text or change which one the cell follows. But correcting an instruction may not repair damage already done.

2. Adding a gene is not editing one

Some gene therapies provide an additional working gene while the original faulty gene remains. “Gene replacement” often means replacing the missing function, not physically replacing the gene.

Gene editing changes DNA at a selected location. In CRISPR-Cas9, a guide molecule directs an enzyme to cut a DNA sequence, and the cell’s response can be used to create a therapeutic change. [2] Gene therapy describes the treatment approach; CRISPR is one of its tools.

Other medicines act on RNA—the working messages cells make from DNA—to reduce protein production. This can silence gene activity without editing DNA. Not every such medicine is classified as gene therapy.

3. Getting into the right cells

A vector is a delivery vehicle carrying therapeutic genetic material. Some are engineered from viruses because viruses are effective at entering cells. An adeno-associated virus, or AAV, can carry a therapeutic gene. Zolgensma, used for spinal muscular atrophy, is one example. [3]

Treatment may happen in vivo—inside the body—with the product administered directly. Alternatively, it happens ex vivo—outside the body: cells are collected, modified in a laboratory, checked and returned. Delivery must suit the target tissue; a system that works for blood-forming cells cannot simply be assumed to work in the brain or another organ. [4]

4. Where treatment has reached patients

Three examples show how specific these treatments remain.

Inherited retinal disease: Luxturna has US Food and Drug Administration (FDA) approval for disease caused by confirmed variants in both copies of RPE65, in patients with viable retinal cells. [5]

Haemophilia B: Hemgenix enables production of factor IX, the deficient clotting protein, in specified adults with this inherited disorder. [6]

Spinal muscular atrophy: Zolgensma supplies a functional copy of SMN1, addressing the shortage of a protein essential to motor nerve-cell survival. [7]

Eligibility depends on the genetic cause, age, disease stage and other clinical factors. Overseas approval does not establish Malaysian registration, availability or funding.

5. Thalassaemia explains the difference

Haemoglobin carries oxygen in red blood cells. Severe beta-thalassaemia impairs production of one of its components, so patients may need regular transfusions. These can cause iron accumulation requiring chelation—treatment to remove excess iron. [8]

Casgevy uses the patient’s own blood-forming stem cells, collected and edited outside the body. It does not directly repair the beta-thalassaemia mutation. Instead, it changes a regulatory region controlling BCL11A, increasing production of fetal haemoglobin—the form predominant before birth—which compensates. [9] [8]

The current US prescribing information lists Casgevy for patients aged two years and older with transfusion-dependent beta-thalassaemia or sickle-cell disease with recurrent vaso-occlusive crises—episodes caused by blocked blood flow. [9] [10]

In the phase 3 trial in patients aged 12 to 35, 32 of the 35 patients with enough follow-up (91%; 95% CI 77–98) achieved at least 12 consecutive months without transfusions while maintaining a weighted average haemoglobin of at least 9 g/dL. The 52 treated patients were followed for a median of 20.4 months in the published interim analysis. This selected, single-arm study had no randomised comparator, so it does not establish a success rate for everyone considered for treatment. [11]

6. When cells become the medicine

T cells are immune cells. In CAR-T therapy, they are genetically engineered to carry a chimeric antigen receptor, an added receptor that recognises a particular target on cancer cells. The modified cells are expanded and administered to the patient.

Approved CAR-T products exist for selected cancers. [12]

CAR-T combines cell therapy with genetic modification. A conventional stem-cell transplant replaces blood-forming cells without deliberately modifying their genes.

7. One treatment does not guarantee one cure

“One-time treatment” describes a dosing schedule, not a guarantee of lifelong success. The effect must persist, enough cells must be modified, and existing damage may remain. What counts as success also differs by disease: freedom from transfusions, improved function or fewer complications.

For Casgevy, treatment includes cell collection, manufacturing and conditioning chemotherapy, which prepares the marrow to receive modified cells and carries substantial risks, including possible effects on fertility. [9] [8] The infusion may happen once. The care continues.

8. What could go wrong?

Risks depend on the product, delivery system, target cells and surrounding treatment. Off-target changes are unintended edits away from the intended DNA site; unwanted changes can also occur at the intended site. [13] Some approaches insert genetic material into chromosomes, potentially disturbing other functions, including control of cell growth. This is called insertional mutagenesis.

What might the patient experience, and what helps?

With Zolgensma, vomiting and raised liver enzymes are among the common adverse reactions. Serious liver injury is a separate major warning. Corticosteroids start one day before infusion and continue afterwards, with liver tests guiding continuation and gradual withdrawal. [14]

With Casgevy, the treatment journey can involve mouth and gut inflammation, fever with very low infection-fighting white cells, and other blood-count reductions, largely from the conditioning chemotherapy. Paracetamol and an antihistamine are given beforehand to reduce infusion reactions, and precautions against seizures and liver complications may accompany the chemotherapy. [9]

CAR-T therapy, such as Kymriah, can cause fever, fatigue, nausea, diarrhoea and infections. Cytokine release syndrome—an excessive inflammatory response—may cause low blood pressure and breathing difficulties, and neurological complications include confusion or seizures. Frequencies vary by product and patient group. Paracetamol and an antihistamine are given beforehand, and tocilizumab, used to treat cytokine release syndrome, must be available for prompt use. Routine preventive systemic steroids are avoided because they may interfere with Kymriah’s activity, although steroids may be required for complications. [15]

Monitoring and access to urgent specialist care remain essential. Long-term follow-up is tailored to the product’s potential delayed risks. [16] Responsibility continues after infusion: the product must remain traceable, adverse reactions must be reported, and follow-up must address delayed harm and loss of benefit. [17] The care plan should also say who continues monitoring if the patient moves or the provider stops operating.

9. Is Malaysia ready?

On 8 February 2024, the Drug Control Authority approved Zolgensma for children under two with spinal muscular atrophy. MOH described it as the first gene-therapy product approved since regulation of Cell and Gene Therapy Products (CGTPs) began on 1 January 2021. [3] The National Pharmaceutical Regulatory Agency (NPRA) issued a second edition of its registration guidance in September 2025. [18]

A conference abstract published in 2025 described University Malaya Medical Centre (UMMC) cell-collection experience for a Phase Ib/II Auxicart-19/22 CAR-T trial, with authors from UMMC, Universiti Malaya and Auxi Therapeutics Sdn Bhd. This documents investigational work, not current recruitment, treatment efficacy or routine availability. [19]

The Malaysia Association for Cell and Gene Therapy (MACGT), whose committee page identifies former MOH Clinical Research Centre director Dr Lim Teck Onn as president, provides another part of the ecosystem. [20] Its registry initiative aims to monitor cell-therapy outcomes. [21]

Annex II of the NPRA guideline states that gene-therapy registration applications will only be accepted after approval by a reference regulatory agency, so developers need to establish the applicable pathway early. [17]

Malaysia has begun assembling the pieces. Connecting them into a dependable patient pathway remains the challenge.

10. Approved does not mean accessible

In February 2026, parliamentary reporting recorded 9,554 patients receiving thalassaemia treatment in public hospitals. Conventional care from infancy to age 40 was estimated at RM3 million per patient; gene therapy at RM10–13 million for a single treatment. These are reported estimates, not Malaysian quotations for a named product or a complete economic comparison. [22]

A family may have the diagnosis and an effective therapy may exist overseas, yet access can remain impossible.

Established alternatives still matter. Haematopoietic stem-cell transplantation—a transplant of blood-forming stem cells—can be potentially curative for selected thalassaemia patients, with its own requirements and risks. [8] In February 2026, the Health Minister reported that 212 Malaysian thalassaemia patients had been cured through donor stem-cell transplantation since 2007. [22]

Malaysia needs product-specific assessments of benefit, durability, total costs and affordability. Outcome-linked payments or staged financing may help manage expenditure; they do not remove the underlying cost.

11. Changing genes—who sets the rules?

Scientific justification, ethical acceptability and legal authorisation are distinct requirements. A risk acceptable for a severe rare disorder may also need a different judgement when effective conventional treatments already exist.

Law and research oversight

NPRA places CGTPs within the Sale of Drugs Act 1952 and Control of Drugs and Cosmetics Regulations 1984 framework. Other laws governing medical practice, private healthcare facilities and biosafety may also apply. Its guidance, issued under Regulation 29, sets out product requirements; ethical review addresses protection of research participants. [17]

Local trials require the relevant Clinical Trial Import Licence (CTIL) or Clinical Trial Exemption (CTX) before importing or manufacturing the investigational product. The pathway requires ethical and Drug Control Authority approval. Trial permission and manufacturing certification are separate from marketing approval. [17]

Consent and continuing responsibility

Patients need to understand alternatives, uncertainty, preparatory treatment, delayed risks and follow-up obligations. This is particularly important when parents are deciding for a seriously ill child.

Our responsibility is to make the uncertainty understandable, not merely obtain agreement.

Genetic information may also reveal information about relatives, so treatment consent, sample storage and future research use should be distinguished.

Future generations and fair access

Somatic editing targets the treated person’s cells and is not intended to pass changes to children. Heritable editing may affect future generations. WHO calls for robust oversight and has warned against clinical germline genome editing; its recommendations are not themselves Malaysian law. [23] [24]

When resources are limited, access decisions should be transparent, clinically justified and attentive to people unable to obtain genetic testing or specialist referral.

12. What should patients ask?

Terms such as “genetic”, “cellular” and “regenerative” do not establish whether a treatment works. Before proceeding, ask:

NPRA provides a public product-status search. Check the specific product, rather than relying on laboratory credentials or a clinic’s reputation. [25] A legitimate trial investigates uncertainty; it does not guarantee a cure.

13. The prescription may never be the same

Gene therapy can give cells new capabilities, but patients still need accurate diagnosis, appropriate selection, competent care and honest explanation.

For the child returning for another transfusion, changing an instruction is not an abstract scientific achievement. It matters when it changes the life that follows.

Sources worth your time

Published 53/2026 · 16 October 2026 · No corrections to date · Corrections policy